Af­ter switch­ing reg­u­la­to­ry plans, As­traZeneca and Dai­ichi re­port pooled ADC da­ta in mu­tant lung can­cer

As­traZeneca and Dai­ichi Sankyo have un­veiled new da­ta on their TROP2-di­rect­ed ADC in pre­treat­ed lung can­cer pa­tients with EGFR-mu­tat­ed dis­ease, adding to their case for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER